Related Experiment Videos

[False positive serological tests for Borrelia burgdorferi in patients with primary antiphospholipid syndrome]

A Selva O'Callaghan1, J Ordi Ros, J M Porcel Pérez

  • 1Servicio de Medicina Interna, Hospital General Vall d'Hebron, Barcelona.

Medicina Clinica
|October 6, 1990
PubMed

Insights

Primary antiphospholipid syndrome (PAPLS) patients show a 14% false positive rate for Lyme disease serology. This can lead to diagnostic errors, especially with neurological symptoms, necessitating confirmatory testing.

Area of Science:

  • Medical diagnostics
  • Immunology
  • Rheumatology

Background:

  • Primary antiphospholipid syndrome (PAPLS) is an autoimmune disorder.
  • Accurate serological testing is crucial for diagnosing infectious and autoimmune diseases.
  • Borrelia burgdorferi causes Lyme disease, diagnosed via serology.

Observation:

  • Serological tests for Borrelia burgdorferi were performed on 27 PAPLS patients.
  • A 14% prevalence of false positive Lyme disease serology was observed in this cohort.

Findings:

  • Patients with PAPLS and false positive Borrelia burgdorferi serology had significantly more neurological involvement (p = 0.012).
  • Indirect Immunofluorescence Assay (IFI) may yield false positives for Borrelia burgdorferi in PAPLS patients.

Implications:

  • False positive Lyme disease serology in PAPLS patients can cause diagnostic errors.
  • Confirmatory testing using ELISA or immunoblotting is recommended for PAPLS patients with positive Lyme serology.
  • This highlights the importance of considering alternative diagnoses and using multiple testing methods in complex autoimmune cases.

Related Concept Videos